These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 9028424)
1. ASHP therapeutic guidelines on angiotensin-converting-enzyme inhibitors in patients with left ventricular dysfunction. This official ASHP practice standard was developed through the ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 16, 1996. Am J Health Syst Pharm; 1997 Feb; 54(3):299-313. PubMed ID: 9028424 [No Abstract] [Full Text] [Related]
2. Promoting use of angiotensin-converting-enzyme inhibitors. Cooke-Ariel H Am J Health Syst Pharm; 1997 Feb; 54(3):264. PubMed ID: 9028418 [No Abstract] [Full Text] [Related]
3. Letter regarding article by Masoudi et al, "national patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction". Sabatini T; Rozzini R; Trabucchi M Circulation; 2005 May; 111(17):e276-7; author reply e276-7. PubMed ID: 15867189 [No Abstract] [Full Text] [Related]
4. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Bart BA; Gattis WA; Diem SJ; O'Connor CM Am J Cardiol; 1997 Apr; 79(8):1118-20. PubMed ID: 9114778 [TBL] [Abstract][Full Text] [Related]
5. ASHP guidelines on the pharmacist's role in home care. Developed through the ASHP Council on Professional Affairs with the assistance of the Executive Committee and Professional Practice Committee of the ASHP Section of Home Care Practitioners and approved by the ASHP Board of Directors on April 27, 2000. Am J Health Syst Pharm; 2000 Jul; 57(13):1252-7. PubMed ID: 10902068 [No Abstract] [Full Text] [Related]
6. Angiotensin converting enzyme inhibitors for heart failure with reduced ejection fraction or left ventricular dysfunction: A complementary network meta-analyses. Guo WQ; Li L Int J Cardiol; 2016 Jul; 214():10-2. PubMed ID: 27055158 [No Abstract] [Full Text] [Related]
7. [ACE inhibitors continue to be first choice in the treatment of heart failure patients]. Gadsbøll N; Pedersen CT Ugeskr Laeger; 2013 May; 175(22):1566-8. PubMed ID: 23721841 [TBL] [Abstract][Full Text] [Related]
8. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure? Ghanem FA; Movahed A Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016 [TBL] [Abstract][Full Text] [Related]
9. Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction--a meta-analysis. Abdulla J; Pogue J; Abildstrøm SZ; Køber L; Christensen E; Pfeffer MA; Yusuf S; Torp-Pedersen C Eur J Heart Fail; 2006 Jan; 8(1):90-6. PubMed ID: 16054435 [TBL] [Abstract][Full Text] [Related]
10. Treating diastolic heart failure: the role of ACE inhibitors. Bettencourt P Rev Port Cardiol; 1999 Sep; 18 Suppl 5():V101-6. PubMed ID: 10582470 [No Abstract] [Full Text] [Related]
11. Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. Shah MR; Granger CB; Bart BA; McMurray JJ; Petrie MC; Michelson EL; Tudor GE; Swedberg K; Stevenson LW; Califf RM; Pfeffer MA Am J Med; 2000 Oct; 109(6):489-92. PubMed ID: 11042239 [No Abstract] [Full Text] [Related]
12. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Bart BA; Ertl G; Held P; Kuch J; Maggioni AP; McMurray J; Michelson EL; Rouleau JL; Warner Stevenson L; Swedberg K; Young JB; Yusuf S; Sellers MA; Granger CB; Califf RM; Pfeffer MA Eur Heart J; 1999 Aug; 20(16):1182-90. PubMed ID: 10448027 [TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction. Abdulla J; Abildstrom SZ; Christensen E; Kober L; Torp-Pedersen C Eur J Heart Fail; 2004 Dec; 6(7):927-35. PubMed ID: 15556055 [TBL] [Abstract][Full Text] [Related]
14. ACE inhibitors in the management and prevention of heart failure. O'Callaghan PA; Walsh MJ Ir Med J; 1995; 88(2):48,50. PubMed ID: 7775143 [No Abstract] [Full Text] [Related]
15. [The use of angiotensin-converting enzyme inhibitors in left ventricular dysfunction (the generalization of the experience of multicenter studies)]. Voronkov LG Lik Sprava; 1998; (5):3-6. PubMed ID: 9793295 [TBL] [Abstract][Full Text] [Related]
16. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Masoudi FA; Rathore SS; Wang Y; Havranek EP; Curtis JP; Foody JM; Krumholz HM Circulation; 2004 Aug; 110(6):724-31. PubMed ID: 15289383 [TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibitors, beta-blockers, and mortality in systolic heart failure. Thornton PL; Ahmed A J Am Coll Cardiol; 2004 Apr; 43(7):1333; author reply 1333-4. PubMed ID: 15063454 [No Abstract] [Full Text] [Related]
18. Aspirin and heart failure: square evidence meets a round patient. Konstam M Congest Heart Fail; 2003; 9(4):203-5. PubMed ID: 12937356 [No Abstract] [Full Text] [Related]
19. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Granger CB; McMurray JJ; Yusuf S; Held P; Michelson EL; Olofsson B; Ostergren J; Pfeffer MA; Swedberg K; Lancet; 2003 Sep; 362(9386):772-6. PubMed ID: 13678870 [TBL] [Abstract][Full Text] [Related]
20. Managing patients with heart failure: the reality of clinical practice. Squire I Eur Heart J; 2005 Dec; 26(24):2611-3. PubMed ID: 16219652 [No Abstract] [Full Text] [Related] [Next] [New Search]